Kornimate/medical-research-clean huggingface dataset:
healing communities study

Conditions: Opioid Use Disorder (OUD)

Summary: this study will test the impact of implementing the communities that helping to end addiction long-term (heal) intervention on opioid overdose deaths within 67 highly affected communities with the goal of reducing opioid overdose deaths by 40%.

the healing communities study (hcs) is a multi-site, parallel group, cluster randomized wait-list controlled trial to test the impact of the communities that heal (cth) intervention, which is designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. the intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder. communities receiving the intervention will be engaged to reach individuals who are at highest risk of overdose death (e.g., out of treatment, leaving jail) and: (1) expand access to and receipt of medication for opioid use disorder (moud) and behavioral treatment, (2) increase the number of individuals retained in treatment beyond 6 months, (3) reduce the risk of fatal overdose through expansion of overdose education and naloxone distribution, and (4) improve prescription opioid safety. in addition, the study will determine (1) the factors that contribute to or impede successful implementation of the cth intervention, (2) the factors that contribute to or impede sustainment of cth intervention, and (3) the incremental costs and cost effectiveness of the cth intervention.

Eligibility criteria:
inclusion criteria: * the community must be located in one of the four participating states: kentucky, ohio, massachusetts, or new york. * at least 30% of the communities selected within each state must be rural. * across all the hcs communities within each state, there must be a minimum of 150 opioid-related overdose fatalities (with at least 22 opioid-related overdose fatalities experienced by the rural communities) and a rate of at least 25 opioid-related overdose fatalities per 100,000 persons, based on 2016 data. * the community must express willingness to address in their response strategy the implementation of moud, overdose prevention training, and naloxone distribution across their community. * the community must express willingness to develop partnerships across health care, behavioral health, and justice settings for evidence-based practices to address opioid misuse, oud, and overdoses. exclusion criteria: * communities that did not meet the aforementioned inclusion criteria were excluded from the hcs.

Keywords: opioid opioid use disorder (oud) overdose addiction naloxone buprenorphine methadone evidence-based practices community engagement
evaluation of counseling for partner notification

Conditions: Sexually Transmitted Infections

Summary: * in the formative stage of the project, we have investigated through qualitative and quantitative studies to identify a potential intervention to promote partner referral for sexually transmitted patients in bangladesh. * we conducted a quasi-randomised trial to evaluate if single session counseling is effective in improving partner referral for patients with sexually transmitted infection.

the study was a quasi-randomized trial, alternating partner referral counselling and standard of care approach for each subsequent patient. first patients was randomly assigned by the project research physician in each clinic then alternative patients allocation was maintained by the study interviewers assigned in each clinic. for index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. counselors were specifically trained to deliver partner referral counselling focusing on five issues related to sti prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an sti. patients in the standard care group received the existing services in the respective clinics, which included clinical consultation, prescription for medication but there was no partner referral counselling per se. in the public clinics, both the counselling and non-counselling group of clients received free medications, while in the ngo clinics they received subsidized fee medications. both groups also received standard, pre-tested anonymous partner referral cards along with a short briefing by the interviewers that index clients need to hand over this card to their partner(s) to bring them to the respective clinics for assessment of sti status. partner referral cards were used to follow-up partner referral by tracking the patient identification number and disease code of cards provided by referred patients. in addition, referral cards were useful for the partners to locate the study clinic, to be entitled to free or subsidized medication, and to distinguish the partners from index cases coming to the clinics.

Eligibility criteria:
inclusion criteria: * each newly diagnosed sti patients * age \> 18 years * who had a sexual exposure in last three months

Keywords: counseling
a study of jaktinib hydrochloride tablets in the treatment of severe novel coronavirus pneumonia

Conditions: Novel COVID-19-Infected Pneumonia

Summary: a randomized, double-blind, placebo parallel control study and is expected to enroll 20-60 eligible patients with severe novel coronavirus pneumonia.


Eligibility criteria:
inclusion criteria: * aged ≥18 years old, regardless of gender; * there is a history of novel coronavirus antigen- or nucleic acid-positive infection within 1-2 weeks; * hrct is consistent with the manifestation of viral pneumonia (judged by the investigator) * participants who voluntarily sign informed consent. exclusion criteria: * participants who cannot take orally, or are suspected to be allergic to jaktinib hydrochloride, similar drugs, or their excipients, or have severe gastrointestinal dysfunction that affects drug absorption; * critical pneumonia participants with other organ failure requiring icu monitoring and treatment; * participants who have received the following treatments within the specified time window before randomization: 1. participants have received janus kinase (jak) inhibitor, interleukin 6 (il-6) inhibitor, il-1 inhibitor, tumor necrosis factor (tnf) inhibitor, t cell or b cell depletion agent, interferon and other immunosuppressive drugs within the first two weeks of randomization, except glucocorticoid; 2. systematically used cyp 3a4 potent inhibitor or potent inducer in the first five drug half-lives at random; * immune deficiency; * participants who have received the novel coronavirus vaccine within 1 week before randomization; * prior to randomization, there were the following active and uncontrolled infections: tuberculosis, hiv, syphilis, mycoplasma, chlamydia, parasites, and viral infections other than sars cov-2 that required systemic anti-infection treatment; * renal diseases requiring dialysis treatment; * pregnant and lactating women; * any other participants that were considered unsuitable by the investigator.
a study of tqb3820 in patients with hematological malignancies

Conditions: Hematological Malignancies

Summary: tqb3820 is a novel cereblon-modulating agent. upon binding to cereblon, a substrate receptor in the cullin4 e3 ligase complex, tqb3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the hematopoietic transcription factors ikaros (ikzf1) and aiolos (ikzf3). modulation of aiolos and ikaros expression has the potential to correct multiple aspects of the immune dysregulation mediated by b cells.


Eligibility criteria:
inclusion criteria: 1. for multiple myeloma cohort 1. patients must have received at least 2 prior therapies; 2. measurable levels of myeloma paraprotein 1. m-protein in serum \>5 g/l; 2. m-protein in urine \>200mg/24h; 3. light chain multiple myeloma without measurable disease in the serum or urine: serum immunoglobulin free light chain ≥ 100 mg/l and abnormal serum immunoglobulin kappa lambda free light chain ratio. 2. for indolent b-nhl 1. progressed after standard treatment or no standard treatment with an established survival benefit is available; 2. imaging in screening showing at least one measurable lesion; in patients with cll/sll, circulating lymphocytes \>= 5.0 × 10\^9/l or lesions greater than 1.5 cm. 3. eastern cooperative oncology group (ecog) performance status score of 0 to 2; 4. life expectancy \>=3 months; 5. adequate organ/system function; 6. female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped; exclusion criteria: 1. patients received allogenic haemopoietic stem cell transplantation, or autologous stem cell transplantation within 3 months; 2. diagnosed and/or treated additional malignancy within 3 years before the first dose; 3. with factors affecting oral medication; 4. toxicity that is \>=grade 2 caused by previous cancer therapy; 5. patients with congenital bleeding or coagulopathy, or are being treated with anticoagulants; 6. patients with uncontrolled infections; 7. has received surgery, chemotherapy, radiotherapy or other anticancer therapies 2 weeks before the first dose; 8. has received chinese patent medicines with anti-tumor indications that national medical products administration(nmpa) approved within 2 weeks before the first dose; 9. pleural effusion, pericardial effusion or ascites that cannot be controlled and need repeated drainage; 10. central nervous system metastases; 11. has participated in other clinical studies within 4 weeks before the first dose; 12. according to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
study of repetitive transcranial magnetic stimulation in the treatment of cognitive impairment in schizophrenia

Conditions: Schizophrenia

Summary: 1. exploration of repetitive transcranial magnetic stimulation（rtms）on working memory and cognitive impairment symptoms of schizophrenia treatment and mechanism. 2. analysis of high-frequency repetitive transcranial magnetic stimulation stimulation to the improvement of negative symptoms and psychotic symptoms.

the study was a randomized double-blind sham-controlled trial for 4 weeks. patients with schizophrenia were treated with 20-hz rtms for 4 weeks to the left dorsolateral prefrontal cortex (added to the ongoing treatment). negative symptoms were assessed with the scale for the assessment of negative symptoms (sans), the positive and negative symptom scale (panss).the auditory steady state responses (assr) were obtained for the assessment of gamma oscillation.and cognitive symptoms were assessed by matrics cognitive test battery (mccb) chinese version and n-back task.

Eligibility criteria:
inclusion criteria: * 1）patients to be diagnosed according to the fourth edition of the diagnostic and statistical manual of mental disorders(dsm-iv) for paranoid schizophrenia；2）20～49 years old；3）duration of 2 \~ 10 years;4）the disease situation is stable， the fluctuation of positive and negative symptom scale（panss）total score ≤10% in last 1 month, and have accepted the current drugs for more than 8 weeks; 5）patients, their families and doctors are agreed that the disease situation is stable and maintained current drug treatment in next month；6）signed an informed consent exclusion criteria: * 1)patients to be diagnosed according to dsm-iv for substance abused,development delayed;2)suffering from serious physical disease and can not accept the treatment;3)repetitive transcranial magnetic stimulation(rtms) contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure;4)the disease situation is not stable， the fluctuation of positive and negative symptom scale（panss）total score \>10% in last 1 month, positive and negative symptom scale（panss）total score \> 60;5)difficult to maintain the current drug treatment for at least 1 month;6）undergoing electroconvulsive therapy（ect）in last 3 months.

Keywords: schizophrenia
impairment of central coherence in restrictive anorexia nervosa (coca)

Conditions: Anorexia Nervosa

Summary: the current etiological pathological model of anorexia nervosa is poly-factorial involving individual genetic and psychological factors, in close interaction with environmental, family and socio-cultural factors. among these factors, this study focuses on the central coherence process (cognitive ability to integrate complex information into a comprehensive meaning), in the active phase of the disease. therefore, patients followed in the addiction service of the nantes university hospital will perform neuropsychological tests assessing executive functions involved in the process of central coherence. impairment of central coherence process could act as a maintenance factor of the disease, particularly in connection with body dysmorphic disorder. the therapeutic perspectives acting on the central coherence process like cognitive remediation deserve to deepen knowledge on the cognitive profile of patients with anorexia nervosa.


Eligibility criteria:
inclusion criteria: * for the patients : * woman. * aged of more than 15 years and 3 months. * followed in the addiction service of the university hospital of nantes (consultations and / or hospitalizations) for restrictive anorexia nervosa (according to the diagnostic criteria of dsm-iv-tr). * french language mastered. * having signed the consent if major and if not the legal representatives have signed the consent (for minors). * for the volunteers : * women. * aged of more than 15 years and 3 months. * french language mastered. * having signed the consent if major and if not the legal representatives have signed the consent (for minors). exclusion criteria: * for the patients : * man * age under 15 years and 3 months old * current renutrition by nasogastric tube * personal history of: * head injury, neurodegenerative diseases, epilepsy unbalanced, unbalanced endocrine disorder, mental retardation * support for current or past cognitive remediation * opposition of the patient and / or his legal representatives if minor * subject under legal guardianship * current participation or in the past to pharmacological research protocol (time since the end of their participation in the protocol less than one year) * french language not mastered * for the volunteers : * man * age under 15 years and 3 months old * current renutrition by nasogastric tube * personal history of: * eating disorders * head injury, neurodegenerative diseases, epilepsy unbalanced, unbalanced endocrine disorder, mental retardation * support for current or past cognitive remediation * opposition of the volunteer and / or his legal representatives if minor * subject under legal guardianship * current participation or in the past to pharmacological research protocol (time since the end of their participation in the protocol less than one year) * french language not mastered
a comparison between ivor-lewis and mckeown minimally invasive esophagectomy

Conditions: Esophageal Cancer

Summary: surgery is still the main treatment for esophageal cancer, however, the complication and mortality rate of open esophagectomy is high. as a result, the thoracoscopic- laparoscopic minimally invasive esophagectomy (mie) was developed. the mie mainly comprised two surgical approaches: mie mckeown approach (cervical anastomosis) and mie ivor-lewis approach (intrathoracicanastomosis). the mie with intrathoracic anastomosis (ivor-lewis) is increasingly used for the treatment of mid and lower esophageal cancers. our study is trying to compare the safety, feasibility, and short-term and long- term outcomes between mie ivor-lewis approach and mie mckeown approach for the treatment of lower thoracic esophageal cancer and esophageal- gastric junction.


Eligibility criteria:
inclusion criteria: (i) patients with clinically staged t1-3n0-2m0 tumors; good cardiopulmonary function; (ii) patients with lower thoracic esophageal tumors and esophageal- gastric junction tumor; (iii) patients without a previous history of cancer; (iv) patients without a previous history of neck or chest surgery; exclusion criteria: (i) cardiopulmonary function not good enough for surgery; (ii) patients with hybrid mie

Keywords: thoracoscopic laparoscopic esophagectomy
compare the scapular muscular endurance, stabilization and dyskinesis parameters of sedentary individuals

Conditions: Scapular Dyskinesis; Sedentary Behavior

Summary: the aim of this study was to compare the parameters of scapular muscular endurance, scapular stabilization, scapular dyskinesia, upper extremity functional status and postural alignment of adult women aged between 40-65 years old who were performing clinical pilates exercises regularly compared with sedentary adult women in the same age group and to determine whether regular exercise had an effect on these parameters.

the aim of this study was to compare the parameters of scapular muscular endurance, scapular stabilization, scapular dyskinesia, upper extremity functional status and postural alignment of adult women aged between 40-65 years old who were performing clinical pilates exercises regularly compared with sedentary adult women in the same age group and to determine whether regular exercise had an effect on these parameters. a total of 70 individuals were included in the study, including 35 individuals performing regular clinical pilates exercises and 35 individuals with sedentary lifestyles. clinical pilates group was selected from the individuals who participated in the exercise program under the control of a physiotherapist regularly for 1 hour, 2-3 days a week for at least 6 months. socio-demographic characteristics, health status and exercise habits of the participants were recorded. for scapular muscle strength assessment, digital hand dynamometer; for scapular muscular endurance assessment, scapular muscular endurance test (smet) and shoulder external rotation fatigue protocol; for the assessment of scapular dyskinesia, lateral scapular slide test (lsst) and lennie test; for assessment of upper extremity functional status, disabilities of the arm, shoulder and hand questionnaire (dash); for the assessment of postural alignment, the new york posture assessment test were used.

Eligibility criteria:
inclusion criteria: * individuals who perform clinical pilates exercises regularly for at least 6 months and at least 2 days a week (pilates group) * individuals who are not actively involved in any sports and do not exercise / physical activity regularly (sedentary group) exclusion criteria: * individuals diagnosed with scoliosis or any other orthopedic and neurological problems * individuals who have had any diagnosis / treatment or had previous surgery due to shoulder and shoulder circumference problems in the last 6 months * individuals with shoulder elevations less than 140 degrees

Keywords: scapular dyskinesis muscle strength muscle endurance pilates exercises
relation between substance use and pain, in patients suffering or surviving from cancer and followed in france

Conditions: Cancer; Pain; Substance Use

Summary: pain is one of the most prevalent symptoms during and after cancer. pain can be the consequence of several situations (disease progression, surgery, and anticancer drugs). however, pain can frequently be associated with a substance use disorder (alcohol, tobacco, drugs, and illicit products such as cannabis). the relationship between substance use and pain is known to be complex and interdependent, i.e. pain can reinforce substance use and substance use can promote pain. however, few data in the literature are available on the use of psychoactive substances in relation to pain in the context of cancer (cancer patients and cancer survivors). moreover, the scientific literature agrees on the fact that these elements are little studied and underestimated in the clinic. the investigators hypothesize that, in cancer patients or cancer survivors, the prevalence of the use of psychoactive substances would be higher in the presence of pain, and would be associated with its intensity and its impact on the quality health-related living (hrqol). the main objective of this study will be to compare, in an adult population of patients suffering from cancer or having had cancer, the prevalence of the consumption of psychoactive substances in painful patients compared to non-painful patients.

patients will answer to an online questionnaire thanks to associations of cancer patients and social networks, in order to explore their substance use and pain status.

Eligibility criteria:
inclusion criteria: - adult patient, male or female, declaring himself as suffering or having suffered from cancer and recruited as such via appropriate communication systems (patient associations, etc.) exclusion criteria: * difficulty to understand french language * residence outside france (will be verified by the information from the department at the start of the questionnaire) * patient close relative * protected adults
the effect of acute phase treatment approaches on creatine kinase and the musculoskeletal system in different types of burns

Conditions: Burn Injury

Summary: there are very few studies indicating the effect of acute phase treatment approaches on creatine kinase and the musculoskeletal system in the physiotherapy and rehabilitation process. rehabilitation in burn patients is a benchmark due to return to pre-burn life. therefore, this study was conducted to determine the effect of acute phase treatment approaches on creatine kinase and the musculoskeletal system in different types of burns.

in the literature, there are very few objective and quantitative studies comparing the effects of standard wound care and rehabilitation period on different burn types in burn patients. thus, our study was designed to investigate the effects of acute phase treatment approaches on creatine kinase and the musculoskeletal system in different types of burns.

Eligibility criteria:
inclusion criteria: * the study were being aged between 18-65 years and having different burn types, and flame, scald, and electrical burns were included in the study. * the burn percentage and mortality percentage were calculated, and patients with a burn percentage of less than fifty percent were included. exclusion criteria: * the study were having a systemic disease, having substance abuse, and having a burn percentage of more than fifty percent.

Keywords: acute-phase burn creatine kinase, mm form, musculoskeletal development treatment effectiveness